VRX

Pullback in pharma has created a compelling buying opportunity

by

The fundamentals are good for the health care sector in general.  Recent news articles on drug pricing/gouging are not likely to effect meaningful change for the overall group dynamics in my opinion or that any changes may be long time in coming and tempered far below market expectations. It’s true that it may compress multiple prices for a while as Evercore #1 ranked biotech analyst Mark Schoenebaum said on CNBC today but I agree with him, its really about innovation.  His favorite picks are Gilead GILD and maintains a price target of $115 on the stock.  I am not as enthusiastic … Read more

VRX, Valeant Pharmaceuticals remains a mystery. What does the CFO see?

by

Overall Score:   Trading Chart: 0                         Analyst Opinion: 1 Strong Buy 5 Buy 10 Hold 3 Underperform 1 Strong Sell 0   Insider Trading:1 Insiders definitely see some potential here leading off with the CFO Schiller’s apprarent open market purchase of 27,800 at $53.64 between 3-1 and 3-12     Management Discussion and Analysis: 1 Government regulation risk is high Significant product liability risk 2012 guidance for revenue in the $3.1-$3.4bn range Company merged with Biovail in Sep 2010 Company claims 9% organic growth in 2011. Results are murky … Read more